{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:34:09Z","timestamp":1790746449697,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.htct.2017.12.003","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T14:32:35Z","timestamp":1520433155000},"page":"120-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation"],"prefix":"10.1016","volume":"40","author":[{"given":"Maira da Costa","family":"Cacemiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u00e7ara Gastaldi","family":"Cominal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia de Souza","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda Pinto","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena L\u00f4bo de","family":"Figueiredo-Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Fernando Bazzo","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fab\u00edola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Xisto","family":"Souto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Albani","family":"Zambuzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiani Gai","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fab\u00edola Atti\u00e9 de","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7037","key":"10.1016\/j.htct.2017.12.003_bib0215","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.htct.2017.12.003_bib0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.htct.2017.12.003_bib0225","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.htct.2017.12.003_bib0230","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.leukres.2006.09.005","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","volume":"31","author":"Speletas","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.htct.2017.12.003_bib0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","author":"Vainchenker","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.htct.2017.12.003_bib0240","doi-asserted-by":"crossref","first-page":"149185","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.htct.2017.12.003_bib0245","doi-asserted-by":"crossref","first-page":"e57911","DOI":"10.1371\/journal.pone.0057911","article-title":"Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker","volume":"8","author":"Rachidi","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.htct.2017.12.003_bib0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"14","key":"10.1016\/j.htct.2017.12.003_bib0255","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.htct.2017.12.003_bib0260","doi-asserted-by":"crossref","first-page":"670580","DOI":"10.1155\/2015\/670580","article-title":"Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest","volume":"2015","author":"Mondet","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"1","key":"10.1016\/j.htct.2017.12.003_bib0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.1995.tb01619.x","article-title":"Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma","volume":"54","author":"Stasi","year":"1995","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2017.12.003_bib0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.htct.2017.12.003_bib0275","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.12659\/MSM.897451","article-title":"The low expression of IL-37 involved in multiple myeloma-associated angiogenesis","volume":"22","author":"Li","year":"2016","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.htct.2017.12.003_bib0280","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12032-013-0778-2","article-title":"Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma","volume":"31","author":"Tsirakis","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.htct.2017.12.003_bib0285","first-page":"31","article-title":"Immunological derangement in hypocellular myelodysplastic syndromes","volume":"8","author":"Serio","year":"2014","journal-title":"Transl Med UniSa"},{"issue":"11","key":"10.1016\/j.htct.2017.12.003_bib0290","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"10.1016\/j.htct.2017.12.003_bib0295","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.htct.2017.12.003_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/875647939000600106","article-title":"Interpretation of the correlation coefficient: a basic review","author":"Taylor","year":"1990","journal-title":"J Diagn Med Sonogr"},{"issue":"6","key":"10.1016\/j.htct.2017.12.003_bib0305","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jir439","article-title":"Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody","volume":"204","author":"Luiza-Silva","year":"2011","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.htct.2017.12.003_bib0310","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-3083.2008.02167.x","article-title":"Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease","volume":"68","author":"Vitelli-Avelar","year":"2008","journal-title":"Scand J Immunol"},{"issue":"7","key":"10.1016\/j.htct.2017.12.003_bib0315","doi-asserted-by":"crossref","first-page":"e2328","DOI":"10.1371\/journal.pntd.0002328","article-title":"Immunological profile of HTLV-1-infected patients associated with infectious or autoimmune dermatological disorders","volume":"7","author":"Coelho-dos-Reis","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.htct.2017.12.003_bib0320","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/QAI.0000000000000412","article-title":"CD11c+CD123Low dendritic cell subset and the triad TNF-\u03b1\/IL-17A\/IFN-\u03b3 integrate mucosal and peripheral cellular responses in HIV patients with high-grade anal intraepithelial neoplasia: a systems biology approach","volume":"68","author":"Guimar\u00e3es","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.htct.2017.12.003_bib0325","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11899-013-0184-z","article-title":"Genetic basis of MPN: beyond JAK2-V617F","volume":"8","author":"Them","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.htct.2017.12.003_bib0330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.2830340411","article-title":"Idiopathic myelofibrosis: a clinical study of 80 patients","volume":"34","author":"Hasselbalch","year":"1990","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.htct.2017.12.003_bib0335","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.htct.2017.12.003_bib0340","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.htct.2017.12.003_bib0345","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses","volume":"16","author":"Gately","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.htct.2017.12.003_bib0350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","article-title":"Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis","volume":"89","author":"Qian","year":"2017","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.htct.2017.12.003_bib0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.htct.2017.12.003_bib0360","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.htct.2017.12.003_bib0365","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14767050701483298","article-title":"CXCL10\/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?","volume":"20","author":"Gotsch","year":"2007","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.htct.2017.12.003_bib0370","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.htct.2017.12.003_bib0375","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00011-017-1025-7","article-title":"The association of urinary interferon-gamma inducible protein-10 (IP10\/CXCL10) levels with kidney allograft rejection","volume":"66","author":"Raza","year":"2017","journal-title":"Inflamm Res"},{"issue":"5","key":"10.1016\/j.htct.2017.12.003_bib0380","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.htct.2017.12.003_bib0385","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2 V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.htct.2017.12.003_bib0390","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0033-1343890","article-title":"JAK2 mutation-related disease and thrombosis","volume":"39","author":"Vannucchi","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.htct.2017.12.003_bib0395","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"10","key":"10.1016\/j.htct.2017.12.003_bib0400","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","article-title":"Global cytokine analysis in myeloproliferative disorders","volume":"31","author":"Ho","year":"2007","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.htct.2017.12.003_bib0405","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.htct.2017.12.003_bib0410","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.htct.2017.12.003_bib0415","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.htct.2017.12.003_bib0420","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.htct.2020.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000}}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113791830018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113791830018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T06:47:28Z","timestamp":1570862848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S253113791830018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S253113791830018X"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2017.12.003","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2017.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}